International
Albania
Bosnia and Herzegovina
Bulgaria
Croatia
Czech Republic
Estonia
Hungary
Latvia
Lithuania
Kosovo
North Macedonia
Poland
Romania
Serbia
Slovakia
Slovenia
Switzerland (German)
Switzerland (French)
Business Development
Medien
Treffen Sie uns
Karriere
Kontakt
Unsere Produkte
Partner & Marken
Referenzen
Über Ewopharma
Vision/Mission
Unsere Werte
Unsere Strategie
Führung
Unternehmensverantwortung
Gebiet
Business Development
Medien
Treffen Sie uns
Karriere
Kontakt
International
Albania
Bosnia and Herzegovina
Bulgaria
Croatia
Czech Republic
Estonia
Hungary
Latvia
Lithuania
Kosovo
North Macedonia
Poland
Romania
Serbia
Slovakia
Slovenia
Switzerland (German)
Switzerland (French)
Medien
PRESSEMITTEILUNGEN
1
2
3
4
Nächste
15.04.2026
Sugemalimab Receives I, A Recommendation in ESMO Guideline for Consolidation Therapy in Patients with Stage Ⅲ NSCLC
Mehr lesen
26.02.2026
BioGaia AB extends long-standing distribution partnership with Ewopharma
Mehr lesen
16.12.2025
Sugemalimab Achieves New Regulatory Milestone: European Commission Approves Stage Ⅲ NSCLC Indication
Mehr lesen
26.07.2024
European Commission Approves Sugemalimab
Mehr lesen
03.06.2024
Allergycare AG becomes part of Ewopharma Group
Mehr lesen
1
2
3
4
Nächste
![[Translate to Switzerland (German):]](/fileadmin/user_upload/Ewopharma_CStone_Sugemalimab_01.png "[Translate to Switzerland (German):]")
